Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty The CRISTAL Randomized Trial

Article Orthopedics

Recommendations from the ICM-VTE: Hip & Knee

[Anonymous]

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2022)

Review Orthopedics

Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis

John E. Farey et al.

Summary: This study aimed to compare the efficacy and associated harms of aspirin and enoxaparin as VTE prophylaxis following elective arthroplasty of the hip or knee. Results showed no significant differences between aspirin and enoxaparin in VTE incidence, mortality, major, or minor bleeding events. However, due to the overall low quality of evidence from the included trials, more high-quality randomized controlled trials are needed to support this conclusion.

ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH (2021)

Add to Collection

Article Orthopedics

Current Practice Trends in Primary Hip and Knee Arthroplasties Among Members of the American Association of Hip and Knee Surgeons: An Update During the COVID-19 Pandemic

Matthew P. Abdel et al.

Summary: At the 2020 Annual Meeting of the American Association of Hip and Knee Surgeons, a audience response poll was conducted via a mobile application to determine current practice patterns among its members, and compared the results to previous polls.

JOURNAL OF ARTHROPLASTY (2021)

Add to Collection

Article Medicine, Research & Experimental

CRISTAL (a cluster-randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study): statistical analysis plan

Verinder Singh Sidhu et al.

Summary: The CRISTAL study aims to compare the effectiveness of aspirin and low molecular weight heparin in preventing symptomatic VTE following hip or knee arthroplasty, nested within the Australian Orthopaedic Association National Joint Replacement Registry. The primary outcome is symptomatic VTE within 90 days. The study was prematurely stopped due to meeting the stopping rule for the primary outcome.

TRIALS (2021)

Add to Collection

Article Orthopedics